Volitionrx Limited

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

VolitionRx reports 240% revenue growth, eyes expansion in veterinary diagnostics

VolitionRx reported strong revenue growth in 2022 but faced a net loss due to higher costs, emphasizing the need for cost management.
The company's focus on commercializing its Nu.Q platform and expanding into veterinary diagnostics presents growth opportunities.
While challenges like increased expenditures and competition exist, VolitionRx's strategic partnerships and product pipeline position it for future success.
Exploring new applications of NETosis technology in animal health and upcoming investor events highlight potential growth avenues for VolitionRx.

VolitionRx reports robust Q1 results, eyes growth in cancer testing

VolitionRx Limited's Q1 2023 performance reflects strong financials, strategic partnerships, and promising revenue from innovative cancer testing products.
The company's strengths include financial stability, strategic collaborations, and growth potential in the veterinary and cancer testing markets.
Challenges in managing expenses, sustaining revenue growth, and strategic focus require careful navigation for continued success.
Opportunities abound in leveraging partnerships, exploring new markets, and proactive initiatives for future growth and market expansion.

VolitionRx reports robust Q2 earnings, poised for growth in cancer diagnostics

VolitionRx Limited delivered a strong performance in Q2 2023, marked by significant revenue growth and a solid financial position, underpinned by cash reserves and milestone payments.
The company's focus on advancing Nu.Q technology, expanding partnerships, and making progress in cancer research bodes well for future growth and innovation.
While facing challenges in scaling sales efforts and managing R&D expenses, VolitionRx has opportunities to drive revenue growth through strategic partnerships and market expansion.

VolitionRx reports robust revenue growth and global expansion opportunities

VolitionRx Limited's Q3 2023 performance showcased strong revenue growth and global expansion in Nu.Q Vet Cancer Test sales.
While facing challenges in regulatory timelines and funding, the company's strategic strengths lie in its innovative products and prudent financial approach.
Opportunities in new product launches, market education, and global expansion position VolitionRx for continued growth and breakthroughs in cancer detection.

VolitionRx reports stellar revenue growth, eyes global expansion with strategic partnerships

VolitionRx Limited's Q4 2023 earnings call highlighted robust revenue growth, strong cash position, and strategic partnerships driving expansion. While facing challenges in financing and operational efficiency, the company's focus on innovative technologies and global market penetration positions it well for future growth and partnerships.

Volitionrx reports revenue growth and eyes cash flow positivity by 2025

Volitionrx Limited (VNRX) is on track for growth with strong revenue performance, successful product launches, and a focus on achieving cash flow positivity. The company faces challenges in expense control and funding strategies but has opportunities in upcoming data releases and licensing deals.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

VolitionRx (NYSE-A:VNRX) Limited revealed that it has been awarded a further $1.5 million in non-dilutive funding from Namur Invest Capital Risk in Belgium. The Austin, Texas-based epigenetics company said Namur Invest's award will fund an early access program for Volition's Nu.Q product portfolio at key sites across the EU, UK, and the United States.

VolitionRx awarded $1.5M in non-dilutive funding

HENDERSON, Nev. , Aug. 3, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced it has been awarded a further $1.5 million non-dilutive funding from Namur Invest Capital Risk in Belgium.

VolitionRx Awarded $1.5 Million in Non-Dilutive Funding

Henderson, Nevada--(Newsfile Corp. - August 3, 2022) - VolitionRx Limited (NYSE American: VNRX) today announced that company executives Cameron Reynolds, CEO, and Scott Powell, Head of Investor Relations, will be attending the Q3 Virtual Investor Summit. During the presentation, VolitionRx Limited's Chief Executive Officer, Cameron Reynolds, will highlight the Company's transformational business strategy, disruptive technology, noteworthy collaborations and partnerships, and the broader going-forward corporate vision.

VolitionRx Limited to Present at Investor Summit Group's Q3 Virtual Conference

HENDERSON, Nev. , Aug. 2, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of 3,450,000 shares of its common stock, including the exercise in full of the underwriter's overallotment option, at a public offering price of $2.00 per share.

VolitionRx Limited Announces Closing of $6.9 Million Underwritten Public Offering of Common Stock

Salarius Pharmaceuticals Inc

Xenetic Biosciences

VolitionRx (NYSE-A:VNRX) Limited has inked a pair of research and development collaborations that will develop targeted, adoptive cell therapies to treat cancer and help advance a drug designed to treat solid and hematologic cancers. First off, the company will collaborate with Xenetic Biosciences (NASDAQ:XBIO) Inc to evaluate the potential combination of Volition's Nu.Q NETs Test and Xenetic's DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers.

VolitionRx Limited inks R&D collaboration deals with Xenetic Biosciences and Salarius Pharmaceuticals in push to develop cancer treatments

FRAMINGHAM, MA / ACCESSWIRE / August 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, and VolitionRx Limited (NYSE AMERICAN:VNRX) ("Volition"), a multi-national epigenetics company, today announced a research and development collaboration to develop Neutrophil Extracellular Traps ("NETs") targeted, adoptive cell therapies for the treatment of cancer. The collaboration is an early exploratory program to evaluate the potential combination of Volition's Nu.Q® NETs Test and Xenetic's DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers.

Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer

VolitionRx (NYSE-A:VNRX) Limited has announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $2.00 per share.  The gross proceeds to Volition from the offering, before deducting the underwriting commissions and other estimated offering expenses payable by Volition, are expected to be $6 million.

VolitionRx announces pricing of underwritten public offering of 3 million shares at a public offering price of $2.00 each

HENDERSON, Nev. , July 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $2.00 per share.

VolitionRx Limited Announces Pricing of $6 Million Underwritten Public Offering of Common Stock

VolitionRx (NYSE-A:VNRX) Limited announced it had presented data about its work on neutrophil extracellular traps, or NETs, at the International Society on Thrombosis and Haemostasis (ISTH) Congress. The firm, in collaboration with researchers at the University of Namur and QUALIblood in Belgium, published a poster presentation entitled "Evaluation and comparison of NETosis biomarkers in sepsis and COVID-19 patients" at the conference.

VolitionRx presents data related to its NETs research at ISTH Congress

HENDERSON, Nev. , July 13, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, in collaboration with researchers at the University of Namur and QUALIblood in Belgium has published a poster presentation entitled "Evaluation and comparison of NETosis biomarkers in sepsis and COVID-19 patients"  at the International Society on Thrombosis and Haemostasis (ISTH) Congress earlier this week.

New NETs Data Presented at International Society on Thrombosis and Haemostasis (ISTH) Congress

VolitionRx (NYSE-A:VNRX) Limited said its Nu.Q NETs test has been CE marked for the detection and evaluation of NETosis, enabling clinical use in over 27 countries across Europe. NETosis is a unique form of cell death characterized by the release of neutrophil extracellular traps, composed of decondensed chromatin, that trap and kill bacteria and viral particles.

VolitionRx says Nu.Q NETs test gets CE mark enabling clinical use in over 27 countries across Europe

to aid the detection and evaluation of diseases associated with NETosis AUSTIN, Texas , May 31, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® NETs test has been CE marked for the detection and evaluation of NETosis, enabling clinical use in more than 27 countries across Europe. NETosis is a unique form of cell death that is characterized by the release of neutrophil extracellular traps ("NETs"), composed of decondensed chromatin, that trap and kill bacteria and viral particles.

Volition Achieves CE Mark for Nu.Q® NETs Test

VolitionRx Limited (NYSE:VNRX ) Q1 2022 Results Conference Call May 12, 2022 8:30 AM ET Company Participants Scott Powell - Executive Vice President of Investor Relations Cameron Reynolds - President and Chief Executive Officer Tom Butera - Chief Executive Officer, Volition Veterinary Diagnostics Development Terig Hughes - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Operator Good morning, ladies and gentlemen. Thank you for standing by.

VolitionRx Limited (VNRX) CEO Cameron Reynolds on Q1 2022 Results - Earnings Call Transcript

VolitionRx (NYSE-A:VNRX) Limited rounded out a strong first quarter by receiving a $10 million milestone payment from Heska Corporation for the company's Nu.Q Vet Cancer Screening Test. In exchange for granting Heska exclusive worldwide rights to sell the Nu.Q Vet Cancer Screening Test for companion animals, Volition has received a $10 million upfront payment and is eligible to receive up to a further $18 million based upon the achievement of near and mid-term milestones.

VolitionRx reports strong 1Q anchored by $10M milestone payment from Heska for Nu.Q Vet Cancer Screening Test

Conference call to discuss financial and operational results scheduled for Thursday, May 12, at 8:30 a.m. U.S. Eastern Time AUSTIN, Texas, May 11, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2022.

VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update

Conference call to take place on Thursday May 12 at 08:30 a.m. Eastern Time Capital Markets Day Friday May 13 at 10:00 a.m.

VolitionRx Limited Schedules First Quarter 2022 Earnings Conference Call and Business Update

AUSTIN, Texas , May 5, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company plans to host a Capital Markets Day in a hybrid format on  Friday, May 13, 2022, at 10 a.m. U.S. Eastern Time.

VolitionRx Limited to Host Capital Markets Day on Friday May 13

VolitionRx (NYSE-A:VNRX) Limited said its Nu.Q Vet Cancer Test has been launched in Asia through SAGE Healthcare Private Limited, which was appointed as a non-exclusive licensee and distributor for the cancer test last year.  Following pre-launch preparations, SAGE hosted a launch event featuring Professor Heather Wilson-Robles, chief medical officer at Volition Veterinary, and Dr Tom Butera, chief executive officer at Volition Veterinary on Friday, April 22.

VolitionRx launches its Nu.Q Vet Cancer Test in Asia through distributor SAGE Healthcare

AUSTIN, Texas , April 25, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of cancers and other life-altering diseases in both humans and animals, has announced the launch of its Nu.Q ® Vet Cancer Test in Asia through its appointed distributor SAGE Healthcare Private Limited. As previously announced, SAGE was appointed in December 2021 to serve as a non-exclusive licensee and distributor for Volition's Nu.Q® Vet Cancer Test in centralized labs in Singapore.

Volition Launches its Nu.Q® Vet Cancer Test in Asia Through its Appointed Distributor SAGE Healthcare

VolitionRx (NYSE-A:VNRX) Limited has announced the appointment of Sharon Ballesteros as the company's new US head of quality and development process. VolitionRx (NYSE-A:VNRX) said Ballesteros has more than 20 years of experience within the in-vitro diagnostics industry with senior program management, quality assurance, and process improvement roles at companies such as Siemens Health Diagnostics, Thermo Fisher, and Agena Bioscience.

VolitionRx appoints industry veteran Sharon Ballesteros as its US head of quality and development process

AUSTIN, Texas , April 6, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment of Sharon Ballesteros as U.S Head of Quality and Development Process. Sharon has over 20 years of experience within the in vitro diagnostics industry with senior program management, quality assurance, and process improvement roles at Siemens Health Diagnostics, Thermo Fisher, and Agena Bioscience.

Volition appoints Sharon Ballesteros as U.S. Head of Quality and Development Process

Reynolds Consumer Products

VolitionRx Limited (VNRX) CEO Cameron Reynolds on Q4 2021 Results - Earnings Call Transcript

VolitionRx (NYSE-A:VNRX) Limited said it has made “good progress” in key areas as it announced its results for the year ended December 31, 2021.  The Austin, Texas-based epigenetics company said it had cash and cash equivalents of around $20.6 million at the year-end, compared with $19.4 million 12 months earlier.

VolitionRx makes ‘good progress' in key areas as it ends 2021 with over $20M in cash

Conference call to discuss financial and operational results scheduled for Thursday, March 31, at 8:00am U.S. Eastern Time ·        Executed global licensing and supply agreement with Heska Corporation to distribute Nu.Q® Vet Cancer Screening Test at the Point of Care with a $10 million upfront payment and up to $18 million based upon the achievement of near/mid-term milestones. Under said agreement will receive ongoing additional revenue for key components and kits.

VolitionRx Limited Announces Full Fiscal Year 2021 Financial Results and Business Update

Heska

VolitionRx (NYSE-A:VNRX) Ltd has struck an exclusive $28 million deal with veterinary diagnostic firm Heska Corporation to license and sell the former's Nu.Q vet cancer screening test at the point-of-care for pets. Heska will receive the worldwide rights to sell the test while VolitionRx (NYSE-A:VNRX) will get a $10 million upfront payment on signing and up to $18 million based upon near to mid-term milestones.

News for Volitionrx Limited Stock (VNRX)